July 8, 2026

Press Release

C4U Corporation

A Divisional Patent of CRISPR-Cas3 Basic Patent Issued in Japan (Patent No. 7886063)

To date, C4U Corporation (“C4U”) has been granted exclusive licenses, including sublicense rights, by the University of Osaka for the inventions related to CRISPR-Cas3, a unique genome editing technology. The above include the invention titled “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD.”
Now, C4U is pleased to announce that the divisional patent for this invention was issued in Japan on June 29, 2026 as Patent No. 7886063.
This invention was initially patented in Japan (Patent No. 6480647), and its divisional applications were subsequently matured into Patent Nos. 7301332 and 7430358 (although third-party oppositions were filed against both patents, decisions were made to maintain them). Then in 2025, Patent No. 773156 was also issued based on a divisional application.
The instant patent (Patent No.xxxxxxx), which matured from the last divisional application, steadily clarifies the scope of rights for the basic CRISPR-Cas3 system.

The invention has also been patented outside of Japan, in Eurasia (Patent No. 040859), Korea (Patent No. 10-2541398), the United States (Patent No. 1180786, No. 12371713), China (Patent No. ZL2018 8 0037636.X), Europe (Patent No. 3636753), Hong Kong (Patent No. 40021189), Australia (Patent No. 2018279457), Mexico (Patent No. 415175), India (Patent No. 548919) and Singapore (Patent No. 11201910729V).
C4U will continue strengthening its intellectual property portfolio with regard to CRISPR-Cas3 technology worldwide and accelerating its application in a wide range of fields, including pharmaceuticals.

About C4U Corporation

C4U is a privately held biotech company originated from the University of Osaka, and focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by the University of Osaka for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.
C4U promotes the development of novel treatments for various diseases, including hereditary disorders, through both in-house research and collaborations with other companies, while simultaneously working to expand its CRISPR-Cas3 platform for application across a wide range of industries. https://www.crispr4u.jp/en/

Contact Information

Address：Yamadaoka 2-8, Suita, Osaka 565-0871, Japan
E-mail：info@crispr4u.com